PGEN
NASDAQ · Biotechnology
Precigen Inc
$5.44
+0.06 (+1.12%)
Open$5.27
Previous Close$5.38
Day High$5.49
Day Low$5.27
52W High$5.47
52W Low$1.38
Volume—
Avg Volume5.12M
Market Cap1.72B
P/E Ratio—
EPS$-0.66
SectorBiotechnology
Analyst Ratings
Strong Buy
9 analysts
Price Target
+1,234.0% upside
Current
$5.44
$5.44
Target
$72.57
$72.57
$43.64
$72.57 avg
$99.14
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 11.02M | 15.49M | 411.38M |
| Net Income | -285,493,972 | -361,181,578 | -34,816,902 |
| Profit Margin | -2,588.2% | -2,458.8% | -8.5% |
| EBITDA | -122,247,606 | -163,248,841 | -49,679,638 |
| Free Cash Flow | — | — | -21,385,787 |
| Rev Growth | -28.9% | -28.9% | +17.8% |
| Debt/Equity | 4.46 | 4.46 | 0.95 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $234.76 | +2.07% | 105.2 | 382.49B |
| AMGN | Amgen Inc | $347.01 | +0.66% | 23.4 | 182.21B |
| GILD | Gilead Sciences Inc | $125.05 | +0.14% | 16.7 | 153.66B |
| VRTX | Vertex Pharmaceuticals Inc | $468.42 | +0.35% | 26.4 | 114.63B |
| REGN | Regeneron Pharmaceuticals | $618.03 | +0.90% | 14.5 | 63.95B |
| ALNY | Alnylam Pharmaceuticals Inc | $288.18 | +0.62% | 64.3 | 37.13B |